Amgen

Update in progress

AMGN (NasdaqGS)

Company RatingAt Risk
SectorHealthcare
IndustryDrug Manufacturers - General

Amgen is a global biopharmaceutical company that discovers, develops, manufactures, and markets human therapeutics. Its portfolio includes Enbrel, Prolia, XGEVA, Repatha, Nplate, Kyprolis, Aranesp, Evenity, Vectibix, Blincyto, Tepezza, Krystexxa, and other medicines. It serves healthcare providers through distributors and collaborates with AstraZeneca, BeONE Medicines, UCB, Kyowa Kirin, and BeiGene. Founded in 1980, based in Thousand Oaks, California.

Company score

Sentiment: -1.78; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 1.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -2.44; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -4.59; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -1.36; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -1.57; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive